Follow
Vivekananda Budamagunta, PhD.
Vivekananda Budamagunta, PhD.
Scientist, Nautilus Biotechnology
Verified email at nautilus.bio
Title
Cited by
Cited by
Year
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ...
Nature communications 11 (1), 1996, 2020
1812020
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ...
Journal of hematology & oncology 13, 1-13, 2020
752020
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity
Y He, W Li, D Lv, X Zhang, X Zhang, YT Ortiz, V Budamagunta, J Campisi, ...
Aging cell 19 (3), e13117, 2020
652020
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ...
European journal of medicinal chemistry 199, 112397, 2020
422020
Cellular senescence in lymphoid organs and immunosenescence
V Budamagunta, TC Foster, D Zhou
Aging (Albany NY) 13 (15), 19920, 2021
372021
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
D Thummuri, S Khan, PW Underwood, P Zhang, J Wiegand, X Zhang, ...
Molecular cancer therapeutics 21 (1), 184-192, 2022
342022
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ...
Journal of Hematology & Oncology 15 (1), 23, 2022
292022
Senescence-associated hyper-activation to inflammatory stimuli in vitro
V Budamagunta, S Manohar-Sindhu, Y Yang, Y He, DO Traktuev, ...
Aging (Albany NY) 13 (15), 19088, 2021
282021
Effect of peripheral cellular senescence on brain aging and cognitive decline
V Budamagunta, A Kumar, A Rani, L Bean, S Manohar‐Sindhu, Y Yang, ...
Aging Cell 22 (5), e13817, 2023
162023
Nanovesicle and extracellular polymeric substance synthesis from the remediation of heavy metal ions from soil
V Budamagunta, N Shameem, S Irusappan, JA Parray, M Thomas, ...
Environmental research 219, 114997, 2023
142023
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
S Khan, P Kellish, N Connis, D Thummuri, J Wiegand, P Zhang, X Zhang, ...
Cell Death Discovery 9 (1), 1, 2023
82023
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
S Khan, V Budamagunta, D Zhou
Advances in Cancer Research 159, 145-184, 2023
62023
DT2216, a BCL-XL proteolysis targeting chimera (PROTAC), is a potent anti T-cell lymphoma agent that does not induce significant thrombocytopenia
Y He, R Koch, V Budamagunta, D Lv, S Khan, X Zhang, JS Wiegand, ...
Blood 134, 303, 2019
32019
Senolytic treatment alleviates doxorubicin‐induced chemobrain
V Budamagunta, A Kumar, A Rani, S Manohar Sindhu, Y Yang, D Zhou, ...
Aging Cell 23 (2), e14037, 2024
22024
A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers
S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ...
Cancer Research 82 (12_Supplement), 5313-5313, 2022
12022
The system can't perform the operation now. Try again later.
Articles 1–15